This project was supported by grants NIH/NIBIB 1K99EB020075 to Pedro Brugarolas and an Innovation Fund Award from the Chicago Innovation Exchange to Brian Popko and Pedro Brugarolas. Prof. Brian Popko is gratefully acknowledged for his mentorship and financial support to the project. Prof. Chin-Tu Chen and the Integrated Small Animal Imaging Research Resource at the University of Chicago are acknowledged for generously sharing laboratory space and equipment. IBA is acknowledged for sponsoring open-access of this article.

CAUTION: All procedures involving the use of radioactive materials must be approved by the local Office of Radiation Safety. When working with radioactive materials wear a lab coat and personal radiation badges. Use two layers of gloves at all times and check hands with a Geiger counter after each step that involves handling radioactivity. If the gloves are contaminated with radioactivity discard and replace outer gloves. Use appropriate shielding, minimize time in contact with the radiation source and maximize distance.
1. One Week before Experiment: Preparation of Materials
<ol>
	<li>Download [18F]3F4AP sequence: Synthera users can log into the Users Database (http://www.iba-radiopharmasolutions.com/products/chemistry) and download the sequence file for 3F4AP. Users of other synthesizers may need to write their own script based on the sequence of steps. Browse through the annotated sequence to become familiar with the steps involved in the synthesis.</li>
	<li>Ensure that there is enough gas for the synthesis. The synthesizer requires compressed gas, either helium or nitrogen. It also requires &#62;75 psi compressed air. Ensure that the pressures are within the recommended by the manufacturer.</li>
	<li>Prepare HPLC mobile phase: prepare 1 L of 50 mM sodium phosphate and 10 mM triethyl amine. Using a pH meter adjust the pH to 8.0 &#177;0.1 by adding dropwise saturated sodium hydroxide while stirring. Filter the solution through a 0.22 &#181;m bottletop filter and add 5% volume of ethanol.</li>
	<li>Dry glassware in the oven overnight.</li>
</ol>
2. Day of Experiment: Before Arrival of Fluorine-18
<ol>
	<li>Using 1 mL syringes, fill reagent vials with the appropriate reagents. For vials 2 and 3 use oven-dried vials and anhydrous solvents kept under argon. Seal the vials with crimp seals using a crimper.
	<ol>
		<li>Fill Vial 1 (11 mm diameter / 2 mL volume vial) with 400 &#181;L of TBA-HCO3 + 800 &#181;L of acetonitrile (MeCN).</li>
		<li>Fill Vial 2 (13 mm / 4 mL vial) with 50 &#181;L of precursor solution 1.0&#160;mg/mL + 450 &#181;L of MeCN.</li>
		<li>Fill Vial 3 (11 mm / 2 mL vial) with 500 &#181;L of MeCN.</li>
		<li>Fill Vial 4 (13 mm / 4 mL vial) with 4 mL of 0.2% oxalic acid in methanol (MeOH).</li>
	</ol>
	</li>
	<li>Condition the QMA (strong anion exchange) and Alumina-N solid phase extraction cartridges. Using a 10 mL syringe, pass 5 mL of 8.4% NaHCO3 drop-wise through the QMA followed by 5 mL of ultrapure deionized Type I water (18.2 &#924;&#937;&#8226;cm at 25 &#186;C). Pass 5 mL of ultrapure water drop-wise through Alumina-N cartridge followed by 5 mL of MeOH + 0.2% oxalic acid.</li>
	<li>Turn on the HPLC and condition the C-18 column with 4 mL per min of mobile phase for 30 min.</li>
	<li>Load a new catalyst cartridge onto the hydrogenator cartridge holder and start a flow of 0.5 mL/min of 100% MeOH. Set the hydrogen regulator to 50 psi and condition the cartridge for 15 min (Figure 2).</li>
	<li>Assemble the Integrated Fluid Processor (IFP) by introducing vials 1 through 4 in their positions, attaching the cartridges and collection vial as shown in Figure 3. Attach a collection vial with a vent needle to the output line of the hydrogenator.</li>
	<li>Start the synthesizer&#39;s software. Enter login and password. Perform pre-run checks on the synthesizer according to manufacturer instructions.</li>
	<li>Click on &#34;Sequences&#34; and then &#34;Open&#34; to load the 3F4AP sequence.</li>
	<li>Load the IFP by clicking the &#34;Load&#34; button on the screen. Type a file name for the run and start the sequence by clicking &#34;Start&#34;. (The automated synthesizer will automatically pause before the 18F loading step.)</li>
	<li>Watch as the synthesizer goes through the routine self-check steps (part one of the sequence). Look at the screen to ensure that there are no warnings or alarms. Pay attention to sounds as the synthesizer flushes lines and preheats reaction vessel in preparation for the run. The temperature indicator should rise and stay at 65 &#186;C. Wait for the signal (auditory beep) indicating that the synthesizer is ready for the 18F transfer.</li>
</ol>
3. Day of Experiment: 18F Labeling
<ol>
	<li>Remotely transfer desired amount of cyclotron-produced 18F from the cyclotron target to 18F vial. Verify the amount of radioactivity and record it with the time of delivery. 
	NOTE: If not using a direct line for 18F- transfer use a prefilled syringe with a needle attached to transfer the activity to the vial through the septum. The amount of starting radioactivity depends on the limits set by the Office of Radiation Safety and the desired amount of final tracer. Typical amount ranges between 50 and 500 mCi.</li>
	<li>Resume sequence on the synthesizer by pressing &#34;Resume&#34;. This will initiate the transfer of the 18F into the QMA.</li>
	<li>Monitor the progression of the synthesis throughout the automated sequence on the computer screen.
	<ol>
		<li>Watch the transfer the 18F from the vial onto the QMA for 90 s. After trapping 18F- on QMA it elutes with TBA-HCO3 solution (vial 1). (Part two of the sequence)</li>
		<li>Monitor the pressure and temperature traces on the synthesizer while the TBA18F is dried under reduced pressure (5 kPa) and heating (100 &#186;C), followed by additional drying and cool down steps. (Part 3 of the sequence)</li>
		<li>Watch the transfer of anhydrous MeCN (vial 3) and precursor solution (vial 2) to the reactor and how it reacts for 1 min at room temperature. The solution should be colorless or very faint yellow. (Part 4 of the sequence)</li>
		<li>Watch the transfer of oxalic acid solution (vial 4) to the reactor. Watch as the solution is pressure transferred from the reactor through alumina-N cartridge to the final product vial. (Part 5 of the sequence)</li>
	</ol>
	</li>
	<li>At the end of the sequence, print out the report, eject the IFP, shut off gas tanks, and close the software.</li>
	<li>While first establishing the procedure, measure the radioactivity in the alumina-N cartridge and the collection vial by separately introducing the cartridge and vial in the dose calibrator. Record the activity and time of measurement. Place the used cartridge in a leaded waste container. Place the collection vial in a shielded container for transport to the next step.</li>
	<li>Using a 1 mL syringe with a 2&#34; needle attached, manually transfer approximately 100 &#956;L of sample of the intermediate product solution into a standard HPLC vial for in-process quality control. Inject 10 &#956;L of this sample into the HPLC to evaluate the purity and identity of the intermediate compound. 
	NOTE: HPLC conditions: XDB 5 &#181;m, 9.4 x 250 mm C18 column. Flow 4 mL/min. Mobile phase (50 mM Na2HPO4, 10 mM TEA, 5% EtOH). Isocratic 15 min.</li>
</ol>
4. Day of Experiment: Hydrogenation
CAUTION: Injection of the product into the hydrogenator has to be done using proper shielding precautions. Hydrogen gas must be properly handled and vented.
NOTE: the hydrogenation reactor can be connected in place of the HPLC column on the synthesizer and controlled using the synthesizer software.
<ol>
	<li>Set up the hydrogenator flow at 0.5 mL/min by starting the synthesizer HPLC sequence. Manually set up hydrogen pressure to 50 psi.
	<ol>
		<li>After finishing the labeling and quenching steps the synthesizer will transfer the intermediate product solution into hydrogenator/HPLC loop.</li>
	</ol>
	</li>
	<li>When the radioactive peak appears on the HPLC software toggle the collection valve to collect the product. Measure radioactivity of crude product using a dose calibrator. 
	NOTE: The crude product should be injected into an automated HPLC system inside a hot cell. After purification, the final product is then collected and dispensed into an aseptic ISO class 5 laminar air flow hot cell as per USP and FDA regulations.</li>
</ol>
5. Day of Experiment: Purification and Preparation of the Dose
<ol>
	<li>Inject crude product into the HPLC and use the automated fraction collector to collect the fractions corresponding to the final product peak. Each tube contains 0.66 mL of solution. 
	NOTE: HPLC conditions: XDB 5 &#181;m, 9.4 x 250 mm C18 column. Flow 4 mL/min. Mobile phase (50 mM Na2HPO4, 10 mM TEA, 5% EtOH). Isocratic 15 min. Collect 4-15 min.</li>
	<li>Measure the radioactivity of each fraction using a dose calibrator and record it. Combine the fractions with highest amounts of radioactivity (typically tubes 14-18).</li>
	<li>Draw the product solution with a 10 mL syringe and pass the sample through 0.22 &#181;m filter into a sterile vial. Record the amount of radioactivity, end of synthesis time and solution volume on the vial label. This is the final dose for injection. Put aside ~0.8 mL of the solution for quality control tests.</li>
</ol>
6. Day of Experiment: Quality Control (QC) Tests
<ol>
	<li>Before dose release: 
	Inspect the dose through lead-shielded glass. The solution must be clear, colorless and free of particulate matter.</li>
	<li>Radiochemical identity:
	<ol>
		<li>For RadioTLC: spot a drop of the sample on a TLC plate side-by-side with the reference standard. Run TLC plate on a TLC chamber using 95% MeOH: 5% acetic acid. Visualize the reference standard under UV illumination and mark its position with pencil.</li>
		<li>Tape the TLC plate to the stage of the radioTLC scanner and record time of the peak. Rf values of the reference standard and radioactive peak must match within 5%.</li>
		<li>For RadioHPLC: run 10 &#181;L of the dose with and without the reference standard on the HPLC. Retention time of the reference standard and the radioactive peak must match. A single coelution peak must be seen on the spiked sample.</li>
	</ol>
	</li>
	<li>For radiochemical purity: measure the area under curve for the radioHPLC and radioTLC target peaks. The area of the target peak must be &#62;95% of the area for all radioactive peaks combined.</li>
	<li>For the specific radioactivity: calculate the specific radioactivity as the amount of radioactivity in the peak (measured on step 5.2) over the mass amount determined from the area under the curve of the UV HPLC trace using a pre-established calibration curve. The specific radioactivity must be higher than 50 mCi/&#181;mol.</li>
	<li>For the residual solvent analysis: measure the amount of residual solvents (MeCN, MeOH) in the dose using gas chromatography. Solvents levels must be &#60; 0.04% for acetonitrile and &#60;3,000 ppm for methanol. The amount of EtOH must be less than 10% w/v.</li>
	<li>For the sterile filter integrity test (bubble point): connect the filter used in step 5.3 to a nitrogen supply equipped with a pressure regulator and submerge the needle in water. Gradually open the gas valve while watching the pressure gauge. The filter should withstand pressures up to 50 psi without bursting as evidenced by the lack of a stream of bubbles from the needle. Increase the pressure beyond 50 psi until a stream of bubbles comes out of the needle. Record this pressure, it is the burst pressure and it must be &#62;50 psi.</li>
	<li>For the radionuclide half-life: measure the radioactivity of the product at two time points &#8805;10 min apart in a dose calibrator. Calculate the half-life using the equation below. The half-life must match that of 18F to within 5 minutes (109 &#177;5 min): 
	t&#189;calculated = 0.693 t &#247; ln (A1/A2) 
	where t is the interval between measurements and A 1, A 2 the activity measured at each time point.</li>
	<li>For the radionuclidic identity and purity: obtain the &#947;-ray spectrum of a sample of the product using a gamma counter. The spectrum should exhibit one single photo-peak at an energy of 511 keV. There should be no other photo-peaks in the spectrum.</li>
	<li>For the endotoxin analysis: measure the endotoxin levels using a LAL chromogenic endotoxin quantitation test. Endotoxin levels must be &#60;1.75 EU/mL for a 1:10 diluted product with a final product volume of 10 mL.</li>
	<li>Document the results from each QC test. Release the dose for animal studies only if all the tests passed.</li>
	<li>Post-dose release: 
	For the sterility test: add a sample of the dose to both fluid thioglycolate and trypticase soy broth. No growth must be seen on the media after 14 days.</li>
</ol>
7. Day of Experiment: Calculations (Table 1)
<ol>
	<li>For the non-decay corrected radiochemical yield (n.d.c. RCY): calculate the n.d.c. RCY as the amount of radioactivity in the final product over the starting radioactivity.</li>
	<li>For the radiolabeling efficiency: calculate the labeling yield as the ratio of radioactivity in the collection vial over radioactivity in the alumina-N cartridge (unincorporated [18F]F-) and the collection vial.</li>
	<li>For the hydrogenation yield: calculate the hydrogenation yield as the amount of radioactivity in the desired peak over the radioactivity injected into the HPLC.</li>
	<li>For the filtering losses: calculate filtering loses as the radioactivity remaining in the filter and syringe over radioactivity before filtering.</li>
</ol>

<ol>
	<li>Valk, P. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Positron emission tomography : basic science and clinical practice. , (2003).</li><li>Phelps, M. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> PET: molecular imaging and its biological applications. , (2004).</li><li>Ametamey, S. M., Honer, M., Schubiger, P. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+imaging+with+PET.">Molecular imaging with PET.</a> Chem Rev. 108 (5), 1501-1516 (2008).</li><li>Oriuchi, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Present+role+and+future+prospects+of+positron+emission+tomography+in+clinical+oncology.">Present role and future prospects of positron emission tomography in clinical oncology.</a> Cancer Sci. 97 (12), 1291-1297 (2006).</li><li>Heiss, W. D., Herholz, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Brain+receptor+imaging.">Brain receptor imaging.</a> J Nucl Med. 47 (2), 302-312 (2006).</li><li>Brugarolas, P., Freifelder, R., Cheng, S. -. H., DeJesus, O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Synthesis+of+meta-substituted+[18F]3-fluoro-4-aminopyridine+via+direct+radiofluorination+of+pyridine+N-oxides.">Synthesis of meta-substituted [18F]3-fluoro-4-aminopyridine via direct radiofluorination of pyridine N-oxides.</a> Chemical Communications. , (2016).</li><li>Jones, R. E., Heron, J. R., Foster, D. H., Snelgar, R. S., Mason, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effects+of+4-aminopyridine+in+patients+with+multiple+sclerosis.">Effects of 4-aminopyridine in patients with multiple sclerosis.</a> J Neurol Sci. 60 (3), 353-362 (1983).</li><li>Davis, F. A., Stefoski, D., Rush, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Orally+administered+4-aminopyridine+improves+clinical+signs+in+multiple+sclerosis.">Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.</a> Ann Neurol. 27 (2), 186-192 (1990).</li><li>Goodman, A. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sustained-release+oral+fampridine+in+multiple+sclerosis:+a+randomised,+double-blind,+controlled+trial.">Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.</a> Lancet. 373 (9665), 732-738 (2009).</li><li>Brugarolas, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Abstracts Of Papers Of The American Chemical Society. , (2016).</li><li>Brugarolas, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+a+PET+tracer+for+MS.">Development of a PET tracer for MS.</a> J Nucl Med Meeting Abstracts. 55 (1), 1124 (2014).</li><li>Brugarolas, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fluorinated+4-aminopyrdines+as+PET+tracers+for+MS.">Fluorinated 4-aminopyrdines as PET tracers for MS.</a> Journal of Nuclear Medicine. 56, 493 (2015).</li><li>Yoswathananont, N., Nitta, K., Nishiuchi, Y., Sato, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Continuous+hydrogenation+reactions+in+a+tube+reactor+packed+with+Pd/C.">Continuous hydrogenation reactions in a tube reactor packed with Pd/C.</a> Chem Comm. (1), 40-42 (2005).</li><li>St&#246;cklin, G., Pike, V. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Radiopharmaceuticals for Positron Emission Tomography-Methodological Aspects. 24, (1993).</li><li>Liu, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Preclinical+evaluation+of+a+high-affinity+18F-trifluoroborate+octreotate+derivative+for+somatostatin+receptor+imaging.">Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.</a> J Nucl Med. 55 (9), 1499-1505 (2014).</li><li>Liu, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=18F-trifluoroborate+derivatives+of+[des-arg(10)]kallidin+for+imaging+bradykinin+b1+receptor+expression+with+positron+emission+tomography.">18F-trifluoroborate derivatives of [des-arg(10)]kallidin for imaging bradykinin b1 receptor expression with positron emission tomography.</a> Mol Pharm. 12 (3), 974-982 (2015).</li><li>Scott, P. J. H., Hockley, B. G., Kilbourn, M. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Radiochemical Syntheses, Volume 1: Radiopharmaceuticals for Positron Emission Tomography. , (2012).</li></ol>

Authors have nothing to disclose.

The preparation of PET tracers requires efficient labeling with minimal user intervention to minimize radiation exposure14. Here, we described the first semi-automated procedure for the radiochemical synthesis of [18F]3F4AP, a PET tracer currently under investigation for imaging demyelination. This semi-automated method produces the radiotracer with high purity and sufficient specific activity for animal studies. Prior methods for the synthesis of this compound relied on manual synthesis6, which significantly limits the amount of radioactive tracer that can be produced. Having an automated method for the synthesis also provides more reproducible yields and makes it easier to transfer the procedure to other laboratories with similar equipment. Future efforts to fully automate the procedure will be instrumental to the production of the tracer in high amounts for studies in large animals or humans.
This procedure uses nucleophilic exchange of 19F for 18F to incorporate the radioisotope into the molecule of interest. The advantages of this reaction are that it is fast and produces almost exclusively the desired product without the need to perform a potentially lengthy purification step to remove excess of precursor. One limitation of using fluoride-exchange labeling reactions such as the one used here is that due to initial mass of cold compound the final specific activity defined as amount of radioactivity in mCi over amount of compound in &#181;mol may be limited. Under our standard conditions, starting with 100-200 mCi of 18F- and 50 &#181;g of precursor, the typical specific activity at the end of synthesis is up to 100-200 mCi/&#181;mol, which appears to be sufficient for preclinical PET imaging studies. Nevertheless, the specific activity may improve by increasing the starting amount for 18F- while keeping the mass amount low. There have been several reports of producing radioligands by fluoride-exchange with high specific activity (1-3 Ci/&#181;mol) by starting with high activity and low precursor amounts15,16.
As with all radiochemical syntheses of PET tracers, it is critical to work quickly in order to minimize radioactive decay. It is also important to minimize the time handling the radioactive materials, use proper shielding and maximize the distance between the radioactive material and the user to minimize radiation exposure. These aspects are particularly important during the second half of the protocol (purification and quality control) in which the user has to manually inject the solution into the HPLC, collect the fractions and filter the final product.
As with all radiochemical syntheses of PET tracers, it is critical to work quickly in order to minimize radioactive decay. It is also important to minimize the time handling the radioactive materials, use proper shielding and maximize the distance between the radioactive material and the user to minimize radiation exposure. These aspects are particularly important during the second half of the protocol (hydrogenation and purification) in which the user has to manually inject the solution into the hydrogenator, collect the fractions, set up the drying procedure, redissolve the product in buffer and filter it. During the filtering step it is easy to lose a large amount of radioactive material in the walls of the vials. Thus, it is important to try to collect all the liquid prior to filtering. Using a greater amount of buffer to dissolve may improve the yield of recovery but its use is discouraged because it will require injecting a larger volume on the HPLC, causing the peak to broaden and increase the volume of the final dose.
In order to troubleshoot and optimize the procedure is important to keep track of the yields of each step. For most steps this is done simply by measuring the amount of radioactivity before and after any step. In the case of the reaction the yields can be calculated through quantification of the HPLC peaks. Table 1 in the Results Section shows the typical yields for each step. Table 2 below lists many of the commonly encountered failures with potential reasons for the failure and how to correct them.
Finally, even though the procedure demonstrated here is specific for the synthesis of [18F]3F4AP, the general workflow and many of the individual steps are common to the synthesis of other compounds17. In this article we also demonstrated the typical QC tests performed on any PET tracer.

The ability to trace a small-molecule drug non-invasively within the human body has great potential towards precision medicine. Among molecular imaging techniques, positron emission tomography (PET) has many favorable characteristics: the high sensitivity of PET detectors allows detection and quantification of very small amounts of radioactive material and the characteristics of the scanners allow accurate spatial mapping of the drug localization1,2,3. For example, PET allows detection and localization of tumors and metastasis based on the level of uptake of a radioactive glucose analog, [18F]FDG4. PET can also provide localization and quantification of specific brain receptors and their occupancy which can be valuable for diagnosing and understanding neurological and psychiatric disorders5. In order to develop a small molecule PET tracer, the compound of interest must be labeled with a positron-emitting isotope, typically 11C or 18F. Between these two radioisotopes, 18F has a longer half-life (109 min vs. 20.3 for 11C), which allows multi-dose and offsite production. Nevertheless, adding 18F to a molecule can be challenging. 18F labeling requires fast reactions compatible with automation relieving the chemist of direct handling of the activity and receiving high-absorbed radiation doses.
We recently described the use of pyridine N-oxides as precursors for the fluorination of pyridines and the use of this chemistry in the radiochemical synthesis of [18F]3F4AP6, a radiofluorinated analog of the FDA-approved drug for multiple sclerosis, 4-aminopyridine (4AP)7,8,9. This novel radiotracer is currently under investigation as a PET tracer for demyelination10,11,12. In this video article, we demonstrate the semi-automated synthesis of this compound using an IBA Synthera Synthesis Unit (henceforth referred to as &#34;the synthesizer&#34;) and an in-house made flow hydrogenation device. The synthesis is based on the reaction shown in Figure 1. Preparation for the procedure takes approximately 1 h, radiolabeling and purification 1.5 h and quality control procedures 0.5 h.

<table><tbody><tr><td>Cyclotron produced [&lt;sup&gt;18&lt;/sup&gt;F]fluoride</td><td>House supplied/Zevacor</td><td>IBA Cyclone 18</td><td>100-200 mCi</td></tr><tr><td>Integrated fluid processor for production FLT/FDG</td><td>ABX</td><td>K-2715SYN</td><td>Cassette used for nucleophilic substitution</td></tr><tr><td>Anhydrous acetonitrile</td><td>Janssen</td><td>36431-0010</td><td>Transfer under nitrogen</td></tr><tr><td>Methanol</td><td>Janssen</td><td>67-56-1</td><td></td></tr><tr><td>ultrapure water</td><td>house supplied</td><td></td><td>Millipore MilliQ system</td></tr><tr><td>TBA-HCO3</td><td>ABX</td><td>808.0000.6</td><td>abx.de</td></tr><tr><td>QMA</td><td>Waters</td><td>WAT023525</td><td>Quaternary methyl ammonium: Anion exchange solid phase extraction cartridge for trap and release of &lt;sup&gt;18&lt;/sup&gt;F&lt;sup&gt;-&lt;/sup&gt; from the target water</td></tr><tr><td>Sodium bicarbonate</td><td>ABX</td><td>K-28XX.03</td><td>Prefilled 5 mL syringes</td></tr><tr><td>Alumina-N</td><td>Waters</td><td>WAT020510</td><td>Alumina-N solid phase extraction cartridge (for trapping unreacted &lt;sup&gt;18&lt;/sup&gt;F&lt;sup&gt;-&lt;/sup&gt;)</td></tr><tr><td>3-fluoro-4-nitropyridine N-oxide</td><td>Synthonix</td><td>76954-0</td><td>Store in desicator. Precursor</td></tr><tr><td>3-fluoro-4-aminopyridine</td><td>Sigma Aldrich</td><td>704490-1G</td><td>Reference standard</td></tr><tr><td>Oxalic acid</td><td>Sigma Aldrich</td><td>75688-50G</td><td></td></tr><tr><td>Sodium phosphate monobasic</td><td>Fisher Scientific&amp;nbsp;</td><td>S80191-1</td><td></td></tr><tr><td>Triethyl amine</td><td>Fisher Scientific&amp;nbsp;</td><td>04885-1</td><td></td></tr><tr><td>Ethanol</td><td>Decon Labs</td><td>DSP-MD.43</td><td>USP</td></tr><tr><td>Final product vial</td><td>ABX</td><td>K28XX.04</td><td></td></tr><tr><td>Millex Filter Syringe</td><td>Millex</td><td>SLGVR04NL</td><td></td></tr><tr><td>10% Pd/C cartridge</td><td>Sigma Aldrich</td><td>THS-01111-12EA</td><td></td></tr><tr><td>11 mm vials + crimp seals</td><td>Fisher Scientific&amp;nbsp;</td><td>03-250-618, 06-451-117, or equivalent</td><td></td></tr><tr><td>13 mm vials + crimp seals</td><td>Fisher Scientific</td><td>06-718-992, 06-718-643, or equivalent</td><td></td></tr><tr><td>HPLC vials</td><td>Fisher Scientific</td><td>03-391-16, 03-391-17, or equivalent</td><td></td></tr><tr><td>SEMIPREP C18 column</td><td>Agilent</td><td>990967-202</td><td></td></tr><tr><td>V-vials</td><td>Alltech</td><td></td><td></td></tr><tr><td>Syringes: 1, 3, 10 mL</td><td>Fisher Scientific</td><td>14-829-10D, 14-829-13Q, 14-829-18G, or equivalent</td><td></td></tr><tr><td>Compressed gases: N&lt;sub&gt;2&lt;/sub&gt;, He, H&lt;sub&gt;2&lt;/sub&gt;</td><td>Airgas</td><td>UHP N300, UHP HE300, UHP H300, or equivalent</td><td></td></tr><tr><td>TLC plates</td><td>Sigma Aldrich</td><td>Z193275, or equivalent</td><td></td></tr><tr><td>&lt;strong&gt;Name&lt;/strong&gt;</td><td>&lt;strong&gt;Company&lt;/strong&gt;</td><td>&lt;strong&gt;Catalog Number&lt;/strong&gt;</td><td>&lt;strong&gt;Comments&lt;/strong&gt;</td></tr><tr><td>&lt;strong&gt;Equipment&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Synthera automated synthesizer</td><td>IBA SA, Belgium, iba-worldwide.com</td><td>Synthera, 250.001</td><td>Automatic synthesis unit</td></tr><tr><td>In-house hydrogenator</td><td>See picture</td><td></td><td>See text description</td></tr><tr><td>Hot cells</td><td>Comecer</td><td></td><td>For manipulating radioactive materials</td></tr><tr><td>RadioTLC scanner</td><td>Eckert and Ziegler</td><td></td><td>For handling sterile materials</td></tr><tr><td>HPLC</td><td>Dionex</td><td>Ultimate 3000</td><td></td></tr><tr><td>Dose calibrator</td><td>Capintec</td><td>CRC15</td><td>Or equivalent</td></tr><tr><td>Gamma counter</td><td>Capintec, 7 Vreeland Road, Florham Park, NJ 07932</td><td>CRC 15, PET-CRC25, or equivalent</td><td>For measuring radioactivity</td></tr><tr><td>Personal dosimeters</td><td>Packard</td><td>Cobra II</td><td>For measuring gamma spectrum</td></tr><tr><td>Personal radiation badges and rings</td><td>Atlantic Nuclear</td><td>Rados Rad-60 Electronic Dosimeter, or equivalent</td><td></td></tr><tr><td>Rotavap + vacuum pump</td><td>Landauer</td><td></td><td></td></tr><tr><td>Lead pigs + syringe shields</td><td>Heidolph</td><td></td><td>Or equivalent</td></tr><tr><td>Geiger counter</td><td>Pinestar</td><td></td><td></td></tr><tr><td>Geiger counter</td><td>Ludlum</td><td>Model 3 + Pancake GM detector, 4801605, 47-1539, or equivalent</td><td></td></tr></tbody></table>

automated radiochemical synthesis of [18f]3f4ap: a novel pet tracer for imaging demyelinating diseases

3-[18F]fluoro-4-aminopyridine, [18F]3F4AP, is a radiofluorinated analog of the FDA-approved drug for multiple sclerosis 4-aminopyridine (4AP). This compound is currently under investigation as a PET tracer for demyelination. We recently described a novel chemical reaction to produce metafluorinated pyridines consisting of direct fluorination of a pyridine N-oxide and the utilization of this reaction for the radiochemical synthesis of [18F]3F4AP. In this article, we demonstrate how to produce this tracer using an automated synthesizer and an in-house made flow hydrogenation reactor. We also show the standard quality control procedures performed before releasing the radiotracer for preclinical animal imaging studies. This semi-automated procedure may serve as the basis for future production of [18F]3F4AP for clinical studies.

The radiochemical synthesis of [18F]3F4AP comprises two steps (Figure 1). The first step is carried out in a fully automated fashion using the synthesis unit (Figure 3). This cassette-based system uses four reagent vials and one reactor vial and has computer-controlled valves that allow transfer and mixing of reagents as well as heating, pressurizing and evacuating the reactor. In addition, it supports standard solid-phase extraction cartridges for separation of reagents. The computer interface allows users to write and modify scripts in order to run their own syntheses. In the case of [18F]3F4AP, the synthesis procedure is comprised of five basic parts. In the first part, the synthesizer performs self-check steps, preheats the reactor and waits for operator&#39;s signal that the 18F is ready. During the second part, the [18F]fluoride is transferred from the 18F vial into the anion exchange cartridge and eluted from the cartridge into the reactor using a solution tetrabutyl ammonium bicarbonate. The third part, the synthesizer azeotropically dries the [18F]fluoride under vacuum to make it reactive towards nucleophilic displacement. In the fourth part, the precursor is automatically added to the reactor where it reacts with the 18F- to generate the labeled compound. Finally, the reaction is quenched by the addition of 0.2% oxalic acid in methanol, which prevents base-promoted decomposition of the product, and the final solution is pressure-transferred to the collection vial after passing through an alumina-N cartridge that traps any unreacted fluoride.
After the labeling step is completed a small sample can be taken for quality control. Running a sample on the HPLC provides confirmation that the labeling step worked and an estimation of the radiochemical purity (Figure 4). Also, from the UV trace on the HPLC the mass amount of product can be calculated using a pre-established calibration curve.
While the in-process quality control HPLC is running, the second reaction step, reduction of the N-oxide and nitro groups, is performed. In order to do this, the labeled product is automatedly injected into an in-house hydrogenation device based on the method published by Yoswathananont et al.13 (Figure 2). This device consists of an HPLC pump and a compressed hydrogen tank connected to the flow hydrogenation device through lines equipped with check valves to prevent back-streaming. The product is pushed by the HPLC pump and mixed with hydrogen in a T-shaped mixer. This mixture is then passed through a small cartridge containing 10% Pd/C catalyst on a solid support. After passing through the catalyst the reduced product is then collected in small fractions.
Following hydrogenation, the crude product is transported and manually injected into the HPLC for purification of the final product (Figure 5). The mobile phase of the HPLC has been selected to be compatible with animal injection. The peaks corresponding to the product are then collected and filtered-sterilized to obtain the final dose.
Prior to releasing the dose for PET imaging studies, quality control tests are performed. These tests are performed to ensure that the tracer is the chemical entity that it is supposed to be and that it is safe for injection. Some of these tests may not be required for injection into animals but it is generally recommended to follow the human use guidelines. Doing so ensures quality of the product, which increases confidence in the results and greatly facilitates future transition to manufacturing the product for human injection.
Table 1 contains the typical synthesis parameters including initial amount radioactivity, initial amount of precursor, yield for each step, specific activity, filtering loses, etc. These parameters are useful troubleshooting occasional failures and future optimization of the procedure.
<img alt="Figure 1" src="/files/ftp_upload/55537/55537fig1.jpg" /> 
Figure 1. Reaction scheme. Radiochemical synthesis consists of labeling by 19F/18F exchange followed by palladium-catalyzed hydrogenation. <a href="http://cloudflare.jove.com/files/ftp_upload/55537/55537fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" src="/files/ftp_upload/55537/55537fig2.jpg" /> 
Figure 2. Hydrogenation system. Schematic of the device. This device is based on the publication by Yoswathananont et al. (ref 13).&#160;
<img alt="Figure 3" src="/files/ftp_upload/55537/55537fig3.jpg" /> 
Figure 3. Scheme of synthesizer integrated fluidic processor (IFP) and reagents. IFP contains four reagent vials, a QMA cartridge and one reactor vial. <a href="http://cloudflare.jove.com/files/ftp_upload/55537/55537fig3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a> 
&#160;
<img alt="Figure 4" src="/files/ftp_upload/55537/55537fig4.jpg" /> 
Figure 4. UV and radioHPLC tracers for intermediate product. 3-fluoro-4-nitropyridine N-oxide has a characteristic absorption at 313 nm. <a href="http://cloudflare.jove.com/files/ftp_upload/55537/55537fig4large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 5" src="/files/ftp_upload/55537/55537fig5.jpg" /> 
Figure 5. UV and radioHPLC tracers for final product. 3-fluoro-4-aminoopyridine absorbs at a 254 nm. <a href="http://cloudflare.jove.com/files/ftp_upload/55537/55537fig5large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Concept</td>
			<td>Mean (n = 4)</td>
			<td>S.D.</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Initial 18F activity (mCi)</td>
			<td>148.0</td>
			<td>44.9</td>
			<td>Start of synthesis</td>
		</tr>
		<tr>
			<td>Precursor amount (&#956;g)</td>
			<td>50</td>
			<td></td>
			<td>Use 50 &#956;L of 1.0 mg/mL stock</td>
		</tr>
		<tr>
			<td>Activity left in QMA (mCi)</td>
			<td>3.0</td>
			<td>1.7</td>
			<td>Measured at the end of labeling step</td>
		</tr>
		<tr>
			<td>Radiolabeling yield</td>
			<td>29.7%</td>
			<td>6.3%</td>
			<td>Act_collection_vial &#247; (Act_collection_vial + Act_AluN)</td>
		</tr>
		<tr>
			<td>Radiochemical purity (HPLC-1)</td>
			<td>&#62; 98%</td>
			<td></td>
			<td>From HPLC-1 QC</td>
		</tr>
		<tr>
			<td>Spec. act. intermediate (mCi/&#956;mol)</td>
			<td>122.9</td>
			<td>29.7</td>
			<td>From HPLC-1 using calibration curve</td>
		</tr>
		<tr>
			<td>Hydrogenation recovery (d.c.)</td>
			<td>74%</td>
			<td>9.0%</td>
			<td>Corrected for decay</td>
		</tr>
		<tr>
			<td>HPLC radiochemical purity (HPLC-2)</td>
			<td>90.7%</td>
			<td>2.9%</td>
			<td>Calculated from HPLC-2</td>
		</tr>
		<tr>
			<td>Drying efficiency</td>
			<td>&#62; 98%</td>
			<td></td>
			<td>Corrected for decay</td>
		</tr>
		<tr>
			<td>Filtering recovery</td>
			<td>93.5%</td>
			<td>1.7%</td>
			<td>Corrected for decay</td>
		</tr>
		<tr>
			<td>Dose volume (mL)</td>
			<td>3.3</td>
			<td></td>
			<td>Collect fractions with highest radioactivity</td>
		</tr>
		<tr>
			<td>Spec. act. final product (mCi/&#181;mol)</td>
			<td>75.5</td>
			<td>30.0</td>
			<td>From HPLC-3 using calibration curve</td>
		</tr>
		<tr>
			<td>Synthesis efficiency</td>
			<td>8.5%</td>
			<td>3.6%</td>
			<td>Non-decay corrected</td>
		</tr>
		<tr>
			<td>Synthesis time (min)</td>
			<td>104</td>
			<td>11.2</td>
			<td></td>
		</tr>
	</tbody>
</table>
Table 1. Radiochemical synthesis parameters.
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Common problems</td>
			<td>Potential reasons and solutions</td>
		</tr>
		<tr>
			<td rowspan="3">[18F]fluoride is not efficiently eluted from the QMA</td>
			<td>&#183; TBA-HCO3 was not prepared correctly. Ensure the concentration is adequate.</td>
		</tr>
		<tr>
			<td>&#183; There are leaks on the TBA-HCO3 vial. Make sure the crimp seal is tight and the septum is not pierced prior to installing it on the IFP.</td>
		</tr>
		<tr>
			<td>&#183; TBA-HCO3 is not in good condition. Order a fresh batch.</td>
		</tr>
		<tr>
			<td rowspan="2">Labeling yield is low</td>
			<td>&#183; There is moisture in the precursor solution. Dry precursor and solvents.</td>
		</tr>
		<tr>
			<td>&#183; Temperature is too low.</td>
		</tr>
		<tr>
			<td rowspan="3">Reaction solution is yellow</td>
			<td>&#183; The product is decomposing due to base. Use less TBA-HCO3.</td>
		</tr>
		<tr>
			<td>&#183; There is too much precursor. Use less precursor.</td>
		</tr>
		<tr>
			<td>&#183; There is too little solvent for the amount of 18F-. Use more solvent.</td>
		</tr>
		<tr>
			<td>Additional peaks on radioHPLC</td>
			<td>&#183; Nitro group is being substituted: reduce the reaction temperature or shorten reaction time.</td>
		</tr>
		<tr>
			<td rowspan="3">Hydrogenation reaction does not work</td>
			<td>&#183; Catalyst is not good. Use a new cartridge.</td>
		</tr>
		<tr>
			<td>&#183; Flow is too fast and does not allow sufficient contact between catalyst and substrate. Decrease flow.</td>
		</tr>
		<tr>
			<td>&#183; Hydrogen pressure is too low. Increase H2 pressure.</td>
		</tr>
		<tr>
			<td>Hydrogen pressure increases dramatically during procedure</td>
			<td>&#183; Cartridge integrity is compromised and solid support is clogging the lines. Stop the flow and shut off the gas. Let radioactivity decay. Remove catalyst cartridge and flush the system. Put a new cartridge.</td>
		</tr>
		<tr>
			<td>Hydrogenation yield is low</td>
			<td>&#183; Too many impurities competing for the catalyst (MeCN, oxalic acid). Decrease amount of impurities or increase mass of precursor (Warning: increasing precursor amount will reduce specific activity).</td>
		</tr>
		<tr>
			<td rowspan="2">Recovery of radioactivity from hydrogenation step is low</td>
			<td>&#183; There is a leak in the system. Check for leaks and backflush into the hydrogen line.</td>
		</tr>
		<tr>
			<td>&#183; Compound is defluorinating in the reactor. Evaluate different reaction conditions (pressure, temperature, flow, etc.).</td>
		</tr>
		<tr>
			<td rowspan="2">Too much radioactivity is lost during filtration</td>
			<td>&#183; Wet the filter prior to use.</td>
		</tr>
		<tr>
			<td>&#183; Use filter with a lower dead volume.</td>
		</tr>
		<tr>
			<td rowspan="4">The final product peak on the HPLC looks broad</td>
			<td>&#183; Too much volume injected. Inject lower amount. Use column with larger diameter.</td>
		</tr>
		<tr>
			<td>&#183; The column is not well conditioned. Condition the column for at least 30 column volumes.</td>
		</tr>
		<tr>
			<td>&#183; pH of the mobile phase is low. Make sure that the pH &#8805; 8.</td>
		</tr>
		<tr>
			<td>&#183; Column is not in good condition. Replace column. Use column compatible with basic pH.</td>
		</tr>
	</tbody>
</table>
Table 2. Troubleshooting guide.

Watch this Scientific Journal Video about Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases at JoVE.com

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

We demonstrate the semi-automated radiochemical synthesis of [18F]3F4AP and quality control procedures.

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

3-[18F]fluoro-4-aminopyridine, [18F]3F4AP, is a radiofluorinated analog of the FDA-approved drug for multiple sclerosis 4-aminopyridine (4AP). This ...

automated-radiochemical-synthesis-18f3f4ap-novel-pet-tracer-for

Research

JoVE Journal

Medicine

9.9K Views.  The University of Chicago. We demonstrate the semi-automated radiochemical synthesis of [18F]3F4AP and quality control procedures.

Video: Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Metastasis is responsible for most cancer deaths. Despite extensive research, the mechanistic understanding of the complex processes governing metastasis remains incomplete. In vivo models are paramount for metastasis research, but require refinement. Tracking spontaneous metastasis by non-invasive in vivo imaging is now possible, but remains challenging as it requires long-time observation and high sensitivity. We describe a longitudinal combined radionuclide and fluorescence whole-body in vivo imaging approach for tracking tumor progression and spontaneous metastasis. This reporter gene methodology employs the sodium iodide symporter (NIS) fused to a fluorescent protein (FP). Cancer cells are engineered to stably express NIS-FP followed by selection based on fluorescence-activated cell sorting. Corresponding tumor models are established in mice. NIS-FP expressing cancer cells are tracked non-invasively in vivo at the whole-body level by positron emission tomography (PET) using the NIS radiotracer [18F]BF4-. PET is currently the most sensitive in vivo imaging technology available at this scale and enables reliable and absolute quantification. Current methods either rely on large cohorts of animals that are euthanized for metastasis assessment at varying time points, or rely on barely quantifiable 2D imaging. The advantages of the described method are: (i) highly sensitive non-invasive in vivo 3D PET imaging and quantification, (ii) automated PET tracer production, (iii) a significant reduction in required animal numbers due to repeat imaging options, (iv) the acquisition of paired data from subsequent imaging sessions providing better statistical data, and (v) the intrinsic option for ex vivo confirmation of cancer cells in tissues by fluorescence microscopy or cytometry. In this protocol, we describe all steps required for routine NIS-FP-afforded non-invasive in vivo cancer cell tracking using PET/CT and ex vivo confirmation of in vivo results. This protocol has applications beyond cancer research whenever in vivo localization, expansion and long-time monitoring of a cell population is of interest.

We describe a protocol for preclinical in vivo tracking of cancer metastasis. It is based on a radionuclide-fluorescence reporter combining the sodium iodide symporter, detected by non-invasive [18F]tetrafluoroborate-PET, and a fluorescent protein for streamlined ex vivo confirmation. The method is applicable for preclinical in vivo cell tracking beyond tumor biology.

Metastasis is responsible for most cancer deaths. Despite extensive research, the mechanistic understanding of the complex processes governing metastasis ...

Cancer Research

Automation of a Positron-emission Tomography (PET) Radiotracer Synthesis Protocol for Clinical Production

The development of new positron-emission tomography (PET) tracers is enabling researchers and clinicians to image an increasingly wide array of biological targets and processes. However, the increasing number of different tracers creates challenges for their production at radiopharmacies. While historically it has been practical to dedicate a custom-configured radiosynthesizer and hot cell for the repeated production of each individual tracer, it is becoming necessary to change this workflow. Recent commercial radiosynthesizers based on disposable cassettes/kits for each tracer simplify the production of multiple tracers with one set of equipment by eliminating the need for custom tracer-specific modifications. Furthermore, some of these radiosynthesizers enable the operator to develop and optimize their own synthesis protocols in addition to purchasing commercially-available kits. In this protocol, we describe the general procedure for how the manual synthesis of a new PET tracer can be automated on one of these radiosynthesizers and validated for the production of clinical-grade tracers. As an example, we use the ELIXYS radiosynthesizer, a flexible cassette-based radiochemistry tool that can support both PET tracer development efforts, as well as routine clinical probe manufacturing on the same system, to produce [18F]Clofarabine ([18F]CFA), a PET tracer to measure in vivo deoxycytidine kinase (dCK) enzyme activity. Translating a manual synthesis involves breaking down the synthetic protocol into basic radiochemistry processes that are then translated into intuitive chemistry &#34;unit operations&#34; supported by the synthesizer software. These operations can then rapidly be converted into an automated synthesis program by assembling them using the drag-and-drop interface. After basic testing, the synthesis and purification procedure may require optimization to achieve the desired yield and purity. Once the desired performance is achieved, a validation of the synthesis is carried out to determine its suitability for the production of the radiotracer for clinical use.

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Positron-emission tomography (PET) imaging sites that are involved in multiple early clinical research trials need robust and versatile radiotracer manufacturing capabilities. Using the radiotracer [18F]Clofarabine as an example, we illustrate how to automate the synthesis of a radiotracer using a flexible, cassette-based radiosynthesizer and validate the synthesis for clinical use.

The development of new positron-emission tomography (PET) tracers is enabling researchers and clinicians to image an increasingly wide array of biological ...

Chemistry

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Functional positron emission tomography (fPET) provides a method to track molecular targets in the human brain. With a radioactively-labelled glucose analogue, 18F-fluordeoxyglucose (FDG-fPET), it is now possible to measure the dynamics of glucose metabolism with temporal resolutions approaching those of functional magnetic resonance imaging (fMRI). This direct measure of glucose uptake has enormous potential for understanding normal and abnormal brain function and probing the effects of metabolic and neurodegenerative diseases. Further, new advances in hybrid MR-PET hardware make it possible to capture fluctuations in glucose and blood oxygenation simultaneously using fMRI and FDG-fPET.
The temporal resolution and signal-to-noise of the FDG-fPET images is critically dependent upon the administration of the radiotracer. This work presents two alternative continuous infusion protocols and compares them to a traditional bolus approach. It presents a method for acquiring blood samples, time-locking PET, MRI, experimental stimulus, and administering the non-traditional tracer delivery. Using a visual stimulus, the protocol results show cortical maps of the glucose-response to external stimuli on an individual level with a temporal resolution of 16 s.

This manuscript describes two radiotracer administration protocols for FDG-PET (constant infusion and bolus plus infusion) and compares them to bolus administration. Temporal resolutions of 16 s are achievable using these protocols.

Functional positron emission tomography (fPET) provides a method to track molecular targets in the human brain. With a radioactively-labelled glucose ...

Behavior

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Positron emission tomography (PET) is an essential molecular imaging technique providing insights into pathways and using specific targeted radioligands for in vivo investigations. Within this protocol, a robust and reliable remote-controlled radiosynthesis of [11C]SNAP-7941, an antagonist to the melanin-concentrating hormone receptor 1, is described. The radiosynthesis starts with cyclotron produced [11C]CO2 that is subsequently further reacted via a gas-phase transition to [11C]CH3OTf. Then, this reactive intermediate is introduced to the precursor solution and forms the respective radiotracer. Chemical as well as the radiochemical purity are determined by means of RP-HPLC, routinely implemented in the radiopharmaceutical quality control process. Additionally, the molar activity is calculated as it is a necessity for the following real-time kinetic investigations. Furthermore, [11C]SNAP-7941 is applied to MDCKII-WT and MDCKII-hMDR1 cells for evaluating the impact of P-glycoprotein (P-gp) expression on cell accumulation. For this reason, the P-gp expressing cell line (MDCKII-hMDR1) is either used without or with blocking prior to experiments by means of the P-gp substrate (&#177;)-verapamil and the results are compared to the ones observed for the wildtype cells. The overall experimental approach demonstrates the importance of a precise time-management that is essential for every preclinical and clinical study using PET tracers radiolabelled with short-lived nuclides, such as carbon-11 (half-life: 20 min).

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Here, we represent a protocol for the fully automated radiolabelling of [11C]SNAP-7941 and the analysis of the real-time kinetics of this PET-tracer on P-gp expressing and non-expressing cells.

Positron emission tomography (PET) is an essential molecular imaging technique providing insights into pathways and using specific targeted radioligands ...

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Routine production of radiotracers used in positron emission tomography (PET) mostly relies on wet chemistry where the radioactive synthon reacts with a non-radioactive precursor in solution. This approach necessitates purification of the tracer by high performance liquid chromatography (HPLC) followed by reformulation in a biocompatible solvent for human administration. We recently developed a novel 11C-methylation approach for the highly efficient synthesis of carbon-11 labeled PET radiopharmaceuticals, taking advantage of solid phase cartridges as disposable &#34;3-in-1&#34; units for the synthesis, purification and reformulation of the tracers. This approach obviates the use of preparative HPLC and reduces the losses of the tracer in transfer lines and due to radioactive decay. Furthermore, the cartridge-based technique improves synthesis reliability, simplifies the automation process and facilitates compliance with the Good Manufacturing Practice (GMP) requirements. Here, we demonstrate this technique on the example of production of a PET tracer Pittsburgh compound B ([11C]PiB), a gold standard in vivo imaging agent for amyloid plaques in the human brains.

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

We report an efficient carbon-11 radiolabeling technique to produce clinically relevant tracers for Positron Emission Tomography (PET) using solid phase extraction cartridges. 11C-methylating agent is passed through a cartridge preloaded with precursor and successive elution with aqueous ethanol provides chemically and radiochemically pure PET tracers in high radiochemical yields.

Routine production of radiotracers used in positron emission tomography (PET) mostly relies on wet chemistry where the radioactive synthon reacts with a ...

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor (SiFA) for Positron Emission Tomography

The para-substituted di-tert-butylfluorosilylbenzene structural motif known as the silicon-fluoride acceptor (SiFA) is a useful tag in the radiochemist&#39;s toolkit for incorporating radioactive [18F]fluoride into tracers for use in positron emission tomography. In comparison to conventional radiolabeling strategies, isotopic exchange of fluorine-19 from SiFA with [18F]fluoride is carried out at room temperature and requires minimal reaction participants. The formation of by-products is thus negligible, and purification is greatly simplified. However, while the precursor molecule used for labeling and the final radiolabeled product are isotopically discrete, they are chemically identical and are thus inseparable during purification procedures. The SiFA tag is also susceptible to degradation under the basic conditions arising from the processing and drying of [18F]fluoride. The &#39;4 drop method&#39;, wherein only the first 4 drops of eluted [18F]fluoride are used from the solid-phase extraction, reduces the amount of base in the reaction, facilitates lower molar amounts of precursor, and reduces degradation.

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

The synthesis of fluorine-18 (18F) labeled radiopharmaceuticals for positron emission tomography typically requires months of experience. When incorporated into a radiotracer, the silicon-fluoride acceptor (SiFA) motif enables a simple 18F-labeling protocol that is independent of costly equipment and preparatory training, while reducing precursor quantity needed and utilizing milder reaction conditions.

The para-substituted di-tert-butylfluorosilylbenzene structural motif known as the silicon-fluoride acceptor (SiFA) is a useful tag in the ...

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

The kynurenine pathway (KP) is a primary route for tryptophan metabolism. Evidence strongly suggests that metabolites of the KP play a vital role in tumor proliferation, epilepsy, neurodegenerative diseases, and psychiatric illnesses due to their immune-modulatory, neuro-modulatory, and neurotoxic effects. The most extensively used positron emission tomography (PET) agent for mapping tryptophan metabolism, &#945;-[11C]methyl-L-tryptophan ([11C]AMT), has a short half-life of 20 min with laborious radiosynthesis procedures. An onsite cyclotron is required to radiosynthesize [11C]AMT. Only a limited number of centers produce [11C]AMT for preclinical studies and clinical investigations. Hence, the development of an alternative imaging agent that has a longer half-life, favorable in vivo kinetics, and is easy to automate is urgently needed. The utility and value of 1-(2-[18F]fluoroethyl)-L-tryptophan, a fluorine-18-labeled tryptophan analog, has been reported in preclinical applications in cell line-derived xenografts, patient-derived xenografts, and transgenic tumor models.
This paper presents a protocol for the radiosynthesis of 1-(2-[18F]fluoroethyl)-L-tryptophan using a one-pot, two-step strategy. Using this protocol, the radiotracer can be produced in a 20 &#177; 5% (decay corrected at the end of synthesis, n &#62; 20) radiochemical yield, with both radiochemical purity and enantiomeric excess of over 95%. The protocol features a small precursor amount with no more than 0.5 mL of reaction solvent in each step, low loading of potentially toxic 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (K222), and an environmentally benign and injectable mobile phase for purification. The protocol can be easily configured to produce 1-(2-[18F]fluoroethyl)-L-tryptophan for clinical investigation in a commercially available module.

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Here, we describe the radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-tryptophan, a positron emission tomography imaging agent for studying tryptophan metabolism, using a one-pot, two-step strategy in a radiochemistry synthesis system with good radiochemical yields, high enantiomeric excess, and high reliability.

The kynurenine pathway (KP) is a primary route for tryptophan metabolism. Evidence strongly suggests that metabolites of the KP play a vital role in tumor ...

Automated Production of [68Ga]Ga-FAPI-46 on the iPHASE MultiSyn Synthesizer

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

[68Ga]Ga-FAPI-46 is a promising new tracer for the imaging of fibroblast activation protein (FAP) by positron emission tomography (PET). Labeled FAP inhibitors (FAPIs) have demonstrated uptake in various types of cancers, including breast, lung, prostate, pancreatic and colorectal cancer. FAPI-PET also possesses a practical advantage over FDG-PET as fasting and resting are not required. [68Ga]Ga-FAPI-46 exhibits enhanced pharmacokinetic properties, improved tumor retention, and higher contrast images than the earlier presented [68Ga]Ga-FAPI-02 and [68Ga]Ga-FAPI-04. Although a manual synthesis protocol for [68Ga]Ga-FAPI-46 was initially described, in recent years, automated methods using different commercial synthesizers have been reported.
In this work, we describe the development of the automated synthesis of [68Ga]Ga-FAPI-46 using the iPHASE MultiSyn synthesizer for clinical applications. Initially, optimization of the reaction time and comparison of the performance of four different solid phase extraction (SPE) cartridges for final product purification were investigated. Then, the development and validation of the production of 0.6-1.7 GBq of [68Ga]Ga-FAPI-46 were conducted using these optimized parameters. The product was synthesized in 89.8 &#177; 4.8% decay corrected yield (n = 6) over 25 min. The final product met all recommended quality control specifications and was stable up to 3 h post synthesis.

This work describes the automated production of up to 1.7 GBq of [68Ga]Ga-FAPI-46 on the iPHASE MultiSyn synthesizer for PET imaging of fibroblast activation protein.

[68Ga]Ga-FAPI-46 is a promising new tracer for the imaging of fibroblast activation protein (FAP) by positron emission tomography (PET). Labeled FAP ...

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)

Biomolecules, including peptides,1-9 proteins,10,11 and antibodies and their engineered fragments,12-14 are gaining importance as both potential therapeutics and molecular imaging agents. Notably, when labeled with positron-emitting radioisotopes (e.g., Cu-64, Ga-68, or F-18), they can be used as probes for targeted imaging of many physiological and pathological processes.15-18 Therefore, significant effort has devoted to the synthesis and exploration of 18F-labeled biomolecules. Although there are elegant examples of the direct 18F-labeling of peptides,19-22 the harsh reaction conditions (i.e., organic solvent, extreme pH, high temperature) associated with direct radiofluorination are usually incompatible with fragile protein samples. To date, therefore, the incorporation of radiolabeled prosthetic groups into biomolecules remains the method of choice.23,24
N-Succinimidyl-4-[18F]fluorobenzoate ([18F]SFB),25-37 a Bolton-Hunter type reagent that reacts with the primary amino groups of biomolecules, is a very versatile prosthetic group for the 18F-labeling of a wide spectrum of biological entities, in terms of its evident in vivo stability and high radiolabeling yield. After labeling with [18F]SFB, the resulting [18F]fluorobenzoylated biomolecules could be explored as potential PET tracers for in vivo imaging studies.1 Most [18F]SFB radiosyntheses described in the current literatures require two or even three reactors and multiple purifications by using either solid phase extraction (SPE) or high-performance liquid chromatography (HPLC). Such lengthy processes hamper its routine production and widespread applications in the radiolabeling of biomolecules. Although several module-assisted [18F]SFB syntheses have been reported,29-32, 41-42 they are mainly based on complicated and lengthy procedures using costly commercially-available radiochemistry boxes (Table 1). Therefore, further simplification of the radiosynthesis of [18F]SFB using a low-cost setup would be very beneficial for its adaption to an automated process.
Herein, we report a concise preparation of [18F]SFB, based on a simplified one-pot microwave-assisted synthesis (Figure 1). Our approach does not require purification between steps or any aqueous reagents. In addition, microwave irradiation, which has been used in the syntheses of several PET tracers,38-41 can gives higher RCYs and better selectivity than the corresponding thermal reactions or they provide similar yields in shorter reaction times.38 Most importantly, when labeling biomolecules, the time saved could be diverted to subsequent bioconjugation or PET imaging step.28,43 The novelty of our improved [18F]SFB synthesis is two-fold: (1) the anhydrous deprotection strategy requires no purification of intermediate(s) between each step and (2) the microwave-assisted radiochemical transformations enable the rapid, reliable production of [18F]SFB.

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB

A facile, one-pot synthesis of N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) was developed based on a non-aqueous, three-step radiochemical process. Using microwave heating, the entire procedure can be completed in less than 30 min, or 60 min with further purification by preparative HPLC. The decay-corrected radiochemical yields (RCYs) were 35-5% (n > 30).

Biomolecules, including peptides,1-9 proteins,10,11 and antibodies and their engineered fragments,12-14 are gaining importance as both potential ...

Biology

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Patients with severe traumatic brain injury (sTBI) have difficulty knowing whether they are accurately expressing their thoughts and emotions because of disorders of consciousness, disrupted higher brain function, and verbal disturbances. As a consequence of an insufficient ability to communicate, objective evaluations are needed from family members, medical staff, and caregivers. One such evaluation is the assessment of functioning brain areas. Recently, multimodal brain imaging has been used to explore the function of damaged brain areas. [18F]-fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG-PET/CT) is a successful tool for examining brain function. However, the assessment of brain glucose metabolism based on [18F]FDG-PET/CT is not standardized and depends on several varying parameters, as well as the patient&#39;s condition. Here, we describe a series of semiquantitative assessment protocols for a region-of-interest (ROI) image analysis using self-produced [18F]FDG tracers in patients with sTBI. The protocol focuses on screening the participants, preparing the [18F]FDG tracer in the hot lab, scheduling the acquisition of [18F]FDG-PET/CT brain images, and measuring glucose metabolism using the ROI analysis from a targeted brain area.

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

[18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography is useful for studying glucose metabolism related to brain function. Here, we present a protocol for an [18F]FDG tracer set-up and semiquantitative assessment of the region-of-interest analysis for targeted brain areas associated with clinical manifestations in patients with severe traumatic brain injury.

Patients with severe traumatic brain injury (sTBI) have difficulty knowing whether they are accurately expressing their thoughts and emotions because of ...

Automated Radiochemical Synthesis of [¹⁸F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Podsumowanie

Przeglądaj więcej filmów

Rozdziały w tym wideo

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Automation of a Positron-emission Tomography (PET) Radiotracer Synthesis Protocol for Clinical Production

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [¹¹C]SNAP-7941

Solid Phase ¹¹C-Methylation, Purification and Formulation for the Production of PET Tracers

¹⁸F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor (SiFA) for Positron Emission Tomography

Radiosynthesis of 1-(2-[¹⁸F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[¹⁸F]fluorobenzoate ([¹⁸F]SFB)

Semi-quantitative Assessment Using [¹⁸F]FDG Tracer in Patients with Severe Brain Injury